Renal denervation (RDN)

Find all the latest content on renal denervation (RDN) published on this website.

Despite the existence of effective antihypertensive drugs, arterial hypertension remains a critical challenge for healthcare systems worldwide. Can catheter-based renal denervation (RDN) play an effective part in reducing, previously untreatable high blood pressure? Follow the latest research in this novel field along with the critical issues of blood pressure monitoring, imaging modalities, tools, devices and techniques as well as vascular access, bleeding risk and adjunctive pharmacotherapy…

Filtered By
Renal denervation

77 results

Current status of renal denervation techniques for the treatment of hypertension (Part 2)

19 May 2021 – From EuroPCR 2021

Watch this session if you want to review the up-to-date indications, device selection and procedural techniques for renal denervation.

This session was originally presented during EuroPCR 2021.

Current status of renal denervation techniques for the treatment of hypertension (Part 2)

Top Interventional Trials presented at ACC.21

07 Jun 2021

Ali Nazmi Calik provides a summary and key take-aways and infographics of 9 major trials of interest to interventional cardiologists presented at ACC.21

Ali Nazmi Calik

Author

Ali Nazmi Calik
Top Interventional Trials presented at ACC.21

Clinical event reductions in high-risk hypertension patients treated with renal denervation

18 May 2021 – From EuroPCR 2021

Watch this session presented by Roland Schmieder in order to learn about the long-term safety and efficacy of renal denervation in high-risk subgroups from the largest renal denervation data set of real-world patients, to understand how clinical event rates could be reduced following renal denervation as compared...

Clinical event reductions in high-risk hypertension patients treated with renal denervation

A review of the RADIANCE-HTN global clinical trial programme: a focus on the TRIO cohort

18 May 2021 – From EuroPCR 2021

Watch this session presented by Ajay Kirtane, Melvin David Lobo and Felix Mahfoud in order to review a history of the field and the recent clinical advancements in renal denervation with the Paradise Ultrasound RDN system, to further examine the recently announced results from RADIANCE-HTN TRIO (blinded, sham-controlled, powered...

A review of the RADIANCE-HTN global clinical trial programme: a focus on the TRIO cohort

RADIANCE-HTN TRIO: key takeaways and implications for the treatment of hypertension

18 May 2021 – From EuroPCR 2021

Watch this session presented by Andrew Sharp in order to learn about the recent clinical advancements in the renal denervation procedure with the Paradise Ultrasound RDN system, and to hear the expert's perspective on the recently announced results from RADIANCE-HTN TRIO (blinded, sham-controlled, powered to demonstrate BP lowering...

RADIANCE-HTN TRIO: key takeaways and implications for the treatment of hypertension

RADIANCE-HTN TRIO: what does this mean for the treatment of hypertension?

18 May 2021 – From EuroPCR 2021

Watch this session presented by Atul Pathak in order to learn about the recent clinical advancements in the renal denervation procedure with the Paradise Ultrasound RDN system, and to hear the expert's perspective on the recently announced results from RADIANCE-HTN TRIO (blinded, sham-controlled, powered to demonstrate BP lowering...

RADIANCE-HTN TRIO: what does this mean for the treatment of hypertension?

Evidence counts: latest Renal Denervation data and the Onyx ONE month DAPT program

19 Oct 2020

On this page you will find a selection of interviews regarding the latest data on renal denervation from TCT Connect 2020, as well as the latest complex sub-analyses from the Onyx ONE Month DAPT program. View a series of short interviews here below!

Evidence counts: latest data from Renal Denervation and the Onyx ONE month DAPT program